A randomized phase III trial on first line metastatic colorectal carcinoma GOLFIG gemcitabine FOLFOX-4 GM-CSF and interleukin 2 chemo-immunotherapy vs standard FOLFOX-4 chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003458-81-IT

Enrollment

178

Registered

2007-02-23

Start date

2005-06-28

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHEMIO-IMMUNOTHERAPY IN ADVANCED COLON-CANCER Level: PT Classification code 10061451

Interventions

Trade Name: Eloxatin IV 1Fl Polv 100mg Product Name: Oxaliplatino Pharmaceutical Form: Solution for infusion INN or Proposed INN: Oxaliplatin CAS Number: 61825-94-3 Concentration unit: mg milligram(s)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Mar 10, 2026